Cronus Pharma Wins FDA Nod for Generic Robenacoxib Injection

Cronus Pharma's FDA approval for a generic Robenacoxib injection signals a new entrant in the veterinary NSAID injectable segment, a category that carries its own GMP compliance obligations under 21 CFR Part 211 and requires demonstrable sterility assurance across the product's shelf life.

Robenacoxib, a COX-2 selective inhibitor, is indicated for pain and inflammation management in companion animals. Generic injectable approvals in this space require bioequivalence data, container-closure integrity validation, and manufacturing controls aligned with FDA's current good manufacturing practice expectations — the same framework governing human parenteral products.

For QA directors and regulatory leads at contract manufacturers or specialty pharma sites handling veterinary injectables, the approval is a reference point: it confirms FDA's continued engagement with the veterinary generic pipeline and reinforces that sterile fill-finish operations serving this segment remain subject to the same inspection rigour as human drug manufacturing.

The source article contains insufficient detail to confirm facility location, manufacturing partner, or launch timeline. Pharma Now will update this report as further regulatory documentation becomes available through FDA's Approved Animal Drug Products database.

Source: Media4Growth via Indian Pharma Post, 26 August 2026.